The liver is a crucial metabolic organ that has a key role in maintaining immune and
endocrine homeostasis. Accumulating evidence suggests that chronic liver disease might …

Background & Aims Long-term outcomes in portopulmonary hypertension (PoPH) are poorly
studied in the current era of pulmonary hypertension management. We analysed the effect of …

Porto-pulmonary arterial hypertension (PoPAH) is a form of pulmonary arterial hypertension
(PAH) that affects patients with cirrhosis, and—to a lesser extent—patients with non-cirrhotic …

Pulmonary hypertension (PH) is a risk factor for morbidity and mortality in patients
undergoing surgery and anesthesia. This document represents the first international …

BACKGROUND Ambrisentan has shown effectiveness in the treatment of Group 1
pulmonary arterial hypertension (PAH). Although portopulmonary hypertension (PoPH) is a …

Abstract Background and Aim As the exact prevalence of portopulmonary hypertension
(PoPH) and the etiology of chronic liver disease (CLD) remain unknown, the present study …

Portopulmonary hypertension (PoPH) is a clinical condition associated with end‐stage liver
disease, described by the coexistence of pulmonary arterial hypertension (PAH) and portal …

Portal hypertension may have major consequences on the pulmonary vasculature due to the
complex pathophysiological interactions between the liver and lungs. Portopulmonary …

Background Tricuspid regurgitation pressure gradient (TRPG) measurement by
echocardiography is recommended as the most objective examination to detect …

Portopulmonary hypertension (PoPH) is a subtype of pulmonary arterial hypertension (PAH)
complicating the course of portal hypertension [1, 2]. Similar to other causes of PAH, PoPH is …